A Phase Ib, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 and Atezolizumab in Patients With Locally Advanced or Metastatic Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 20 Dec 2017
At a glance
- Drugs Atezolizumab (Primary) ; Vonlerolizumab (Primary) ; Bevacizumab
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Genentech
- 14 Dec 2017 Status changed from recruiting to active, no longer recruiting.
- 22 Aug 2017 Planned End Date changed from 29 Dec 2018 to 12 Aug 2018.
- 22 Aug 2017 Planned primary completion date changed from 29 Dec 2018 to 12 Aug 2018.